{"Background:": [187, 372, 0], "Methods:": [373, 1467, 0], "Discussion:": [1468, 1955, 0], "Trial Registration:": [1956, 2102, 0], "Rationale for convalescent plasma as a therapy for COVID-19": [3296, 4295, 0], "Expanded Access Program and Emergency Use Authorization": [4296, 6551, 0], "Clinical trials of COVID-19 convalescent plasma": [6552, 9292, 0], "Goal of this trial": [9293, 10301, 0], "Background": [2103, 10301, 1], "Design and oversight": [10311, 12143, 0], "Collection of convalescent plasma": [12144, 14290, 0], "Selection of convalescent plasma for the trial": [14291, 17973, 0], "Trial participants": [17974, 18447, 0], "Randomization and treatment groups": [18448, 19696, 0], "Blinding": [19697, 20933, 0], "Outcomes": [20934, 22048, 0], "Data Collection, Monitoring, and Dissemination": [22049, 23567, 0], "General approach to analysis": [23751, 27030, 0], "Interim analyses": [27031, 28489, 0], "Primary analysis of the primary outcome": [28490, 30010, 0], "Additional analyses of the primary outcome": [30011, 32304, 0], "Sample Size and Power": [32305, 34026, 0], "Analysis of secondary and safety outcomes": [34027, 34514, 0], "Statistical analysis": [23568, 34514, 1], "Methods": [10302, 34514, 1], "Trial Status": [37488, 38282, 0], "Discussion": [34515, 38282, 1], "Supplementary Material": [38283, 38311, 0]}